Recent Posts

Pages: 1 ... 7 8 [9] 10

POLITICS / Dr. Oz tries to correct Trump on cost of GLP-1 weight-loss drugs

« Last post by agate on October 27, 2025, 09:07:59 pm »

This reported interchange between President Trump and Dr. Oz is one more instance where Trump is trying to put a lie over on the public--this time trying to persuade us that the new GLP-1 weight-loss drugs will be $150 instead of their current $1,000-plus per month. Interestingly, Dr. Oz immediately follows up his polite correction with this incredibly meaningless statement:

Quote

Oz stepped up to the podium once again, saying that Trump "will be happy with the result and until he is, we're not gonna close those negotiations."

"The result"?

From MedPage Today (October 20, 2025):

"Awkward moment": Dr. Oz interrupts Trump at Oval Office

OCREVUS (ocrelizumab) / (ECTRIMS) Ocrelizumab may double serious infection risk in MS

« Last post by agate on October 26, 2025, 04:06:15 pm »

From MedPage Today (September 28, 2025)--"Ocrelizumab may double serious infection risk in MS":

https://www.medpagetoday.com/meetingcoverage/ectrims/117680

The abstract:

Long-term safety risks among patients with multiple sclerosis treated with ocrelizumab: An observational study

Alise K. Carlson1, Mengke Du1, Scott Husak1, Jeffrey Cohen1, Robert J. Fox1, Daniel Ontaneda1

1Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, OH, United States
Introduction:

The use of B-cell depleting therapies for treatment of multiple sclerosis (MS) has been associated with good control of disease activity and prevention of long-term disability accrual but may also be associated with increased risk of serious infections.

Objectives/Aims:

To characterize the magnitude of this risk in a large real-world population.

Methods:

Retrospective data from the Mellen Center for Multiple Sclerosis Treatment and Research at the Cleveland Clinic were used to analyze the incidence of serious infections in MS patients treated with ocrelizumab compared to a propensity-matched cohort of patients treated with platform injectable therapies, to evaluate differences in time from treatment onset to first serious infection, and to examine the relationship between immunoglobulin levels and incidence of serious infections in patients treated with ocrelizumab. Incidence of serious infections between those treated with ocrelizumab aged <55, 55-60, and >60 years was also assessed.

Results:

The risk for serious infection was higher in patients treated with ocrelizumab (n = 2,551) than for patients treated with platform injectable therapies (n = 1,307) in a propensity-matched cohort (OR 1.98 [1.52, 2.59], p = <0.001). The rate of serious infections per 100 person-years for the ocrelizumab and platform injectable therapies groups were 4.21 and 2.64, respectively. Time to first serious infection was shorter in the ocrelizumab-treated cohort (HR 1.86 [95% CI 1.45, 2.39]). Hypogammaglobulinemia was not associated with increased risk of serious infection(s) in ocrelizumab-treated patients (1.36 [95% CI 0.99, 1.89], p = 0.07 for IgG and 1.21 [95% CI 0.90, 1.63], p = 0.21 for IgM, respectively). Within the ocrelizumab cohort, analysis based on age demonstrated no significant differences in risk for serious infection (55-60, OR 1.11 [95% CI, 0.74-1.65]; >60, OR 1.38 [95% CI, 0.91-2.09]).

Conclusion:

These findings pertaining to risk of serious infection are consistent with those reported in the clinical trials and extension studies, and other observational real-world cohorts. The results provide the magnitude of this risk in comparison to platform treatment and may facilitate shared decision making between patients and providers to select disease modifying therapy.

TREATMENTS / (Abst.) Comprehensive systematic review of Ibudilast for progressive MS

« Last post by agate on October 25, 2025, 02:55:56 pm »

From PubMed (October 25, 2025)--"A comprehensive systematic review of Ibudilast as a neuroprotective therapy for progressive multiple sclerosis":

https://pubmed.ncbi.nlm.nih.gov/41135262/

THE PRACTICAL SIDE OF BEING MULTIPLY SCLEROSED / Social Security 2026 COLA to be 2.8%

« Last post by agate on October 24, 2025, 09:33:25 pm »

If MS has made gainful employment impossible, many people rely on Social Security disability checks for income. The annual cost of living adjustment (COLA) for 2026 has been announced, according to this from the AARP (October 24, 2025)--2.8%, slightly more than last year.

Social Security Sets COLA at 2.8% for 2026

ANNOUNCEMENTS / Re: About links here--update

« Last post by agate on October 23, 2025, 07:20:23 pm »

I'd like to think that this place has been doing something right even if there aren't many followers.

For some time now URLs have been shortened using another way that is safer all around. Bitly and tinyurl are no longer part of the scene here.

URLs longer than one or two lines will be shortened, for readability.

MS - RESEARCH AND NEWS / (Abst.) Sex differences in relapse-independent and relapse-associated disability progression in RRMS

« Last post by agate on October 22, 2025, 09:24:43 pm »

From Therapeutic Advances in Neurological Disorders (September 23, 2025)--"Sex differences in relapse-independent and relapse-associated disability progression in relapsing-remitting multiple sclerosis: A real-world inverse-probability weighted study":

https://journals.sagepub.com/doi/full/10.1177/17562864251376807

THE PRACTICAL SIDE OF BEING MULTIPLY SCLEROSED / In praise of the sock aid

« Last post by agate on October 21, 2025, 09:22:11 pm »

If you happen to have back problems, possibly MS-related, and you can't get socks onto your feet without weird contortions and considerable pain, I recommend one of these sock-aids. I recently acquired one and am finding it very helpful. I don't like using this forum to advertise products but this particular one is proving so useful that I decided to mention it.

Pages: 1 ... 7 8 [9] 10

MS Speaks